Everolimus Directly Suppresses Insulin Secretion Independently of Cell Growth Inhibition

Everolimus, an orally administered mammalian target of rapamycin inhibitor, has been widely used as an immunosuppressant and an anticancer agent. Whereas everolimus can control recurrent hypoglycemia in patients with insulinoma, possibly through tumor regression and/or the direct inhibition of insul...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Endocr Soc
Main Authors: Suzuki, Luka, Miyatsuka, Takeshi, Himuro, Miwa, Nishio, Rie, Goto, Hiromasa, Uchida, Toyoyoshi, Nishida, Yuya, Kanazawa, Akio, Watada, Hirotaka
Formato: Artigo
Idioma:Inglês
Publicado em: Endocrine Society 2018
Assuntos:
Brief Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6007247/
https://ncbi.nlm.nih.gov/pubmed/29942923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2017-00475
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados